- Chimeric Therapeutics (CHM) enters into a strategic manufacturing partnership with global contract testing and manufacturing company, WuXi ATU, to support its Chimeric CAR T-cell programs
- Under the agreement, Chimeric will transfer certain manufacturing and analytical testing technologies to WuXi, who will support process and analytical development and conduct testing activities
- The new partnership will allow Chimeric to speed up clinical manufacturing readiness for its multiple planned clinical trials
- Chimeric expects the cost of the agreement to be funded from existing cash reserves
- CHM shares are up 3.57 per cent, trading at 14.5 cents
Chimeric Therapeutics (CHM) has entered into a strategic manufacturing partnership with global contract testing and manufacturing organisation WuXi ATU to support the company’s Chimeric CAR T-cell programs.
Under the agreement, Chimeric will transfer certain manufacturing and analytical testing technologies to WuXi ATU, who will support process and analytical development and conduct testing activities for the cell programs.
The new partnership will enable Chimeric to accelerate clinical manufacturing readiness for new CAR T assets and to scale CAR T manufacturing to support multiple, simultaneous, multicenter CAR T clinical trials in the future.
The initial focus under the agreement will be on Chimeric’s two autologous CAR T-cell therapies for solid tumours.
“With its extensive experience in cGMP manufacturing and analytical testing, as well as its seamless platform process for CAR T-cell production, WuXi ATU is uniquely positioned to support the acceleration and expansion of the CHM 1101 and CHM 2101 development programs,” said CEO Jennifer Chow.
CHM 1101 is currently being evaluated in a single-site phase one clinical trial to treat patients with recurrent or progressive glioblastoma.
The program will leverage on WuXi’s scalable manufacturing and analytical testing capacity to enable future expansion of the program to multiple additional clinical trial sites and additional solid tumor indications, including metastatic melanoma.
Meanwhile, CHM 2101 is currently in late preclinical development for multiple gastrointestinal (GI) cancers, including colorectal cancer, gastric cancer, pancreatic cancer, and GI neuroendocrine tumors (NETs).
The company believes that the program will take advantage of Wuxi’s end-to-end platform process for Car T manufacturing and testing which will prepare the company for the planned first in-human study.
Chimeric has not disclosed the financial value of the partnership but has assured that the cost of the agreement is expected to be funded from existing cash reserves.
CHM shares were up 3.57 per cent, trading at 14.5 cents as of 11:52 am AEST.